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Abstract: Elevated plasma concentrations of homocysteine, a sulfur-containing amino acid, 
are a risk factor for coronary, cerebral and peripheral artery disease. Next to other factors, 
drugs used for the prevention or treatment of cardiovascular disease may modulate plasma 
homocysteine levels. Thus, a drug induced homocysteine increase may counteract the desired 
cardioprotective effect. The aim is to summarize the current knowledge on the effect of two 
important classes of drugs, lipid-lowering drugs and anti-hypertensive drugs, on homocysteine 
metabolism. Among the lipid-lowering drugs, especially the ﬁbric acid derivatives, which are 
used for treatment of hypertriglyceridemia and low HDL-cholesterol, are associated with an 
increase of homocysteine by 20%–50%. This increase can be reduced, but not totally avoided 
by the addition of folic acid, vitamin B12 and B6 to ﬁbrates. HMG-CoA reductase inhibitors 
(statins) do not inﬂuence homocysteine concentrations substantially. The effects of nicotinic 
acid and n3-fatty acids on the homocysteine concentrations are less clear, more studies are 
necessary to clarify their inﬂuence on homocysteine. Antihypertensive drugs have also been 
studied with respect to homocysteine metabolism. A homocysteine increase has been shown after 
treatment with hydrochlorothiazide, a lowering was observed after treatment with ß-blockers, 
but no effect with ACE-inhibitors. The clinical signiﬁcance of the homocysteine elevation by 
ﬁbrates and thiazides is not clear. However, individual patients use these drugs for long time, 
indicating that even moderate increases may be important. 
Keywords: homocysteine, ﬁbrates, diuretics, cardiovascular disease 
Aim of the review
At present, the meaning of elevated homocysteine concentrations for cardiovascular 
risk is unclear. Retrospective case-control studies show a clear, strong association 
of hyperhomocysteinemia and elevated risk, however, in prospective observational 
studies, the association is less strong (Homocysteine studies collaboration 2002). 
One reason for this discrepancy can be the inﬂuence of the disease on homocysteine 
concentrations. Indeed, research has shown that a number of drugs frequently given 
to patients with CVD that might also have an inﬂuence on homocysteine. 
Therefore, this review will 1) brieﬂy summarize the epidemiological and biochemi-
cal evidence of the association between homocysteine and CVD, 2) summarize the 
effect of lipid-lowering drugs on homocysteine, 3) summarize the effect of anti-hy-
pertensive drugs on homocysteine, and ﬁnally, comment on the clinical implications 
of drug-induced increase of homocysteine. 
Link between homocysteine levels  
and cardiovascular disease
Cardiovascular diseases remain the main cause of mortality in industrialized coun-
tries and become increasingly prevalent in developing countries. The risk to develop Vascular Health and Risk Management 2007:3(1) 100
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cardiovascular disease is mainly attributable to a number of 
known risk factors, that are in ﬁrst instance hyperlipidemia, 
hypertension, smoking and diabetes mellitus. However, other 
risk factors must also contribute to cardiovascular disease, 
as the primary risk factors can not explain all cases of CVD. 
Among other risk factors, hyperhomocysteinemia was rec-
ognized during the last decades as a preventable risk factor 
present in about 30% of patients with coronary heart disease 
(Boushey et al 1995) and in 10%–15% of the general popula-
tion (Nygard et al 1995; Dierkes et al 2001a). The association 
between elevated homocysteine concentrations and coronary, 
cerebral or peripheral artery disease was investigated in 
numerous epidemiological studies with either retrospective 
or prospective study design. Furthermore, clinical trials are 
underway or have been closed to investigate whether a low-
ering of elevated homocysteine concentrations will reduce 
recurrent cardiovascular disease (Clarke 2005). In addition, 
a huge number of biochemical studies was performed to 
investigate the effect of homocysteine on endothelial cells, 
smooth muscle cells, thrombocytes, or clotting factors.
Epidemiological studies
In order to have an overview on the epidemiological studies 
conducted on the issue, several meta-analyses have been per-
formed. The ﬁrst meta-analysis was published more than 10 
years ago by Boushey and colleagues (1995), who included 
27 studies relating homocysteine to arteriosclerotic vascular 
disease (Table 1). Most of the following meta-analyses con-
sidered more prospective trials that had been published in the 
meantime, and reported divergent results for retrospective 
studies compared with prospective studies (Table 1). Overall, 
retrospective studies show a stronger association of homo-
cysteine and CVD than prospective studies. In addition, the 
association of homocysteine to stroke seems to be stronger than 
the association to coronary heart disease. Most meta-analyses 
calculated the odds ratios for an increase of plasma homocys-
teine of 5 µmol/L. However, it has to be taken into account that 
the standard deviation of plasma homocysteine measured in 
healthy populations is in the magnitude of 3–4 µmol/L. There-
fore, an increase of 5 µmol/L represents a fairly large increase 
in homocysteine. According to this, it can be concluded, that 
elevated homocysteine is a signiﬁcant but modest risk factor 
for coronary, cerebral, or peripheral artery disease (Wald et al 
2002; Homocysteine Studies Collaboration 2002).
Biochemical studies 
Homocysteine exerts its atherogenic properties via several 
mechanisms, which have not been fully elucidated to date. 
In vitro studies showed that homocysteine is cytotoxic to en-
dothelial cells, promotes the proliferation of smooth muscle 
cells, and leads to several interactions with platelets, clotting 
factors, and lipids (Welch and Loscalzo 1998; Thambyrajah 
and Townend 2000; Li et al 2002). In addition, homocysteine 
can disrupt the folding and processing of newly synthesized 
proteins in the endoplasmic reticulum (Wilson and Lentz 
2005). Homocysteine can also induce oxidative stress and is 
able to reduce the bioavailability of nitric oxide, mechanisms 
leading to endothelial dysfunction.
However, since most of the results are derived from in 
vitro studies using supraphysiological concentrations of 
homocysteine, their signiﬁcance to the in vivo processes 
of atherogenic plaque formation and disruption have to be 
determined. 
Endothelial function 
Measurement of endothelial function offers an elegant in 
vivo method to study an atherogenic effect of a compound, 
since endothelial vasodilation of the brachial artery corre-
lates well with the function of coronary arteries (Celermaijer   
et al 1992). It was shown in a number of studies that hyper-
homocysteinemia impairs endothelial-dependent vasodila-
tion, which is regarded as an early and preclinical sign of 
atherosclerosis (Tawakol et al 1997; Chambers et al 1999; 
Thambyrajah et al 2001). Mechanisms leading to endothelial 
dysfunction by hyperhomocysteinemia depend probably on 
the generation of reactive oxygen species, decreased bio-
availability of nitric oxide (NO) and concurrent elevation of 
asymmetric dimethylarginine (ADMA), a strong inhibitor of 
the NO synthase (Nappo et al 1999; Böger et al 2001).
Effects of anti-hyperlipidemic drugs
Hyperlipidemia is the term for a number of conditions 
of dysregulated lipid metabolism which require different 
treatment regimens. While the risk associated with elevated 
total cholesterol and elevated LDL-cholesterol is well   
investigated, the signiﬁcance of elevated triglycerides, low 
HDL-cholesterol or elevated Lp(a) for CVD risk is less clear 
(Assmann et al 1998; Jeppesen et al 1998). Hypercholester-
olemia is a primary risk factor for cardiovascular disease. 
Large-scale randomized trials have shown that lipid-lowering 
with HMG-CoA reductase inhibitors (statins) reduce relative 
risk for cardiovascular events or death both in primary and 
in secondary prevention (Gotto 2005). Therefore, statins 
are widely used for the treatment of hypercholesterolemia. 
Hypertriglyceridemia, however, is less well established as 
risk factor for cardiovascular disease. Furthermore, results Vascular Health and Risk Management 2007:3(1) 101
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Table 1  Overview of meta-analyses on homocysteine and CVD since 1995
Year and author   No. of studies  No of retrospective/  Main results (OR and 95% CI) 
  Included  prospective studies 
1995 Boushey   27  24 / 3  Hcy + 5 µmol/L: 
      1.6 (1.4–1.7) Men, CAD
      1.8 (1.3–1.9) Women, CAD
      1.5 (1.3–1.9) Cerebrovasc. 
2000 Moller  12  8 / 4  Hcy > 95th percentile:
      3.97 (3.07–5.12) Cerebrovasc. 
2000 Cleophas  33  22 / 11  elevated Hcy (no further def.)
      1.49 (1.33–1.67) prospective CAD
      1.62 (1.50–1.74) retrospect. CAD
2002 Kelly   14  11 / 3  HHcy (binary variable) 
      1.79 (1.61–2.0) Stroke 
2002 Wald   20  – / 16   IHD, 8 Stroke Hcy + 5µmol/L:
      1.32 (1.19–1.45) IHD 
      1.59 (1.29–1.96) Stroke 
2002 Ford   38 CHD  26 / 12  Hcy + 5 µmol/L
      1.23 (1.07–1.41) prospective
      1.70 (1.50–1.93) retrospective
  24 stroke   17 / 7  1.58 (1.35–1.85) prospective
      2.16 (1.65–2.82) retrospective
2002 Hcy Studies   30  IHD: 15 / 12  Hcy – 25% 
Collaboration       0.83 (0.77–0.89) prospective IHD
      0.67 (0.62–0.71) retrospect. IHD 
    Stroke: 5 / 8  0.77 (0.66–0.90) prospective stroke
      0.86 (0.73–1.01) retrospect. stroke
Abbreviations: CAD, coronary artery disease; CHD, coronary heart disease; CI, conﬁdence interval; OR, odds ratio; IHD, ischemic heart disease; Hcy, homocysteine; HHcy, 
hyperhomocysteinemia.
of randomized clinical trials for treatment of hypertri-
glyceridemia have been less convincing than trials with 
statins (The BIP study group 2000; The DAIS investigators 
2001; The FIELD study 2005). Low HDL-cholesterol is 
frequently associated with elevated triglycerides. Drugs of 
choice for the treatment of hypertriglyceridemia and low 
HDL-cholesterol are the ﬁbrates which act via activating 
peroxisome proliferation-activated receptors α (PPAR α), 
nicotinic acid, or derivatives from this compound which 
act primarily on the adipocytes, and n3-fatty acids. All of 
these compounds have been investigated with respect on 
their effect on the homocysteine concentration, which will 
be summarized within this review. 
Fibrates 
Fibric acid derivatives (fenoﬁbrate, bezaﬁbrate, ciproﬁbrate, 
gemﬁbrozil) are the drugs of choice for the treatment of hy-
pertriglyceridemia (Fruchart 2001). Upon treatment, plasma 
triglycerides may be reduced by 30%–60% and cholesterol by 
20%–25%, while HDL-cholesterol will be increased (Brown 
1987). Fibrates represent synthetic ligands of PPAR α, leading 
to increased activation of genes involved in lipid metabolism 
and increased fatty acid metabolism (Fruchart et al 2001). 
The effect of ﬁbrates on homocysteine has been investi-
gated both in short-term studies and in long-term epidemio-
logical studies. The long term studies have been designed 
with the aim of proving the protective effect of ﬁbrates on 
cardiovascular risk and in subgroups, the effect on homocys-
teine has been studied in stored samples (Genest et al 2004; 
Keech et al 2005). 
Numerous short-term studies revealed that administration 
of fenoﬁbrate was associated with an elevation of homocyste-
ine of the magnitude of 40%–50% (Dierkes et al 1999; Landray 
et al 1999; Giral et al 2001; Bisonnette et al 2001). Ciproﬁ-
brate was less often investigated (Harats et al 2001). These 
studies were all short-term studies lasting for 6–12 weeks. 
However, re-evaluation of randomized clinical trials with 
ﬁbric acid derivatives conﬁrmed the homocysteine increase 
also after longer periods: In the Diabetes Atherosclerosis In-
tervention Study (DAIS), 418 patients with diabetes mellitus 
type 2 and mild lipid abnormalities received fenoﬁbrate (n = 
207) or placebo (n = 211) for a mean period of 40 months. At 
baseline and at the end of the study, a coronary angiography 
was performed (DAIS study group 2001). Homocysteine 
increased in the fenoﬁbrate group on average by 5.6 ± 6.3 
µmol/L and remained unchanged throughout the study in Vascular Health and Risk Management 2007:3(1) 102
Dierkes et al
the placebo group. Increase in homocysteine did not alter 
results obtained in the angiography (neither mean segment 
diameter, mean lumen diameter nor % stenosis). The abso-
lute increase in homocysteine was similar over the whole 
range of baseline homocysteine levels, leading to higher 
percent increase in those with initially low homocysteine 
concentrations (Genest et al 2004). Folate and cobalamin 
were not affected by fenoﬁbrate treatment. In a multinational, 
randomised controlled trial, the FIELD study (Keech et al 
2005), 4895 patients with type 2 diabetes mellitus received 
200 mg fenoﬁbrate daily. Fenoﬁbrate did not signiﬁcantly 
reduce the risk of the primary outcome of coronary events. 
The median plasma homocysteine concentration increased 
about 4 µmol/L. There was a slight increase in pulmonary 
embolism (p = 0.022), but whether changes in homocysteine 
are causal for embolism in this study is unknown.
Administration of bezaﬁbrate also leads to an increase 
of total homocysteine in short-term studies, as shown by our 
group (Dierkes et al 1999) and others (Jonkers et al 1999). The 
homocysteine increase was somewhat lower than the increase 
observed after fenoﬁbrate, and was about 20%–35%. 
Some conﬂicting data are available on the effect of gem-
ﬁbrozil on homocysteine. Gemﬁbrozil differs in some aspects 
from beza- or fenoﬁbrate, as it does not involve PPAR α 
activation. In a study of our group, we did not observe any 
effect of gemﬁbrozil on plasma homocysteine concentrations 
in 22 hyperlipidemic men (Westphal 2001). In contrast, a re-
cent re-evaluation of the Lopid Coronary Angiography Trial 
(LOCAT), a homocysteine increase of 18% was observed in 
178 patients treated with gemﬁbrozil for 16 months while no 
change of homocysteine was observed in the placebo group 
(n = 184) (Syvanne 2004). Differences between studies are the 
administered dose of gemﬁbrozil (900 mg versus 1200 mg), 
study duration (6 weeks versus 16 months) and sample size 
(n = 22 vs n = 178). 
In conclusion, it is evident that the elevation of homocys-
teine by ﬁbric acid derivatives is a class effect which is es-
pecially observed after fenoﬁbrate. Mechanisms responsible 
for this effect may be 1) effects of ﬁbrates on the creatine-
creatinine pathway (Hottelart et al 1999, 2002; Broeders et al 
2000; Lipscombe and Bargman 2001), 2) the downregulation 
of the renal cyclo-oxygenase enzyme (COX-2), thus inhibi-
tion of synthesis of renal vasodilating prostaglandins (Wilson 
et al 1995; Yoshinari et al 1998; Khan et al 2002), and 3) a 
yet unknown effect of PPAR α activation on homocysteine 
metabolism (Legendre et al 2002; Luc et al 2004). 
Concerning creatine-creatinine metabolism, it must be 
noted that both fenoﬁbrate and bezaﬁbrate cause increases 
of serum creatinine concentrations, but obviously not due to 
an alteration of the glomerular ﬁltration rate (Hottelart et al 
1999). Obviously, fenoﬁbrate induces an increased creatine 
turnover rate. However, an increase in creatine turnover may 
also cause an increase of homocysteine since the methyl 
group of creatine is donated by S-adenosylmethionine, 
rendering S-adenosylhomocysteine and thus homocysteine 
(Mudd and Poole 1975).
Downregulation of the renal COX-2 enzyme system by 
PPAR α activation leads to decreased synthesis of vasodilat-
ing prostaglandins and may then reduce glomerular ﬁltration 
rate. The action of these vasodilating prostaglandins is es-
pecially important in patients with impaired renal function 
(Khan et al 2002).
Recently, it has been shown that the homocysteine 
increasing effect of ﬁbrates depend on the activation of 
PPAR α in rodents (Legendre et al 2002; Luc et al 2004). 
Fenoﬁbrate mixed into the diet caused a doubling of homo-
cysteine concentration in wild-type mice, while in PPAR α 
deﬁcient mice, no change of homocysteine concentrations 
was observed. In a similar experiment, PPAR α-knock out 
mice had initially slightly lower homocysteine concentrations 
than wild-type mice, and there was no increase in homocys-
teine in the knock-out mice after 2 weeks administration of 
fenoﬁbrate at a dose of 100 mg/kg. In rats, fenoﬁbrate caused 
an increase of homocysteine by more than 80% (Legendre   
et al 2002; Luc et al 2004). In contrast, Stulc et al (2005) did 
not ﬁnd any increase in homocysteine after treatment with 
rosiglitazone. Rosiglitazone, a novel class of antidiabetic 
drugs, is an agonist of PPAR γ receptors.
At present, there are no data suggesting an effect of ﬁ-
brates on folate or cobalamin metabolism. In the short-term 
studies, no effect of ﬁbrates was observed on vitamin levels 
(Dierkes et al 1999, 2001b; Bissonnette et al 2001; Westphal 
et al 2001; Milionis et al 2003). Additionally, there was no 
chance in folate or cobalamin levels during the DAIS study 
(Genest et al 2004). Furthermore, macrocytic anemia or other 
signs of vitamin deﬁciency are not associated with long-term 
treatment with ﬁbrates. 
In healthy populations, vitamin supplementation with 
folic acid and/or cobalamin can reduce circulating homocys-
teine concentrations effectively by about 25% (Homocysteine 
Lowering Trialists’ Collaboration 1998, 2005). Therefore, 
addition of vitamins to fenoﬁbrate may be an option to de-
crease homocysteine concentrations during ﬁbrate treatment. 
This was investigated in studies using folic acid, vitamin B12 
and vitamin B6 in nutritional doses (Dierkes et al 2001b) or 
using a high dose of folic acid (5–10 mg) (Stulc et al 2001; Vascular Health and Risk Management 2007:3(1) 103
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Melenovsky et al 2003; Mayer et al 2003, 2005). The uniform 
result of these studies is that vitamin or folic acid addition 
to fenoﬁbrate can reduce the increase of plasma homocys-
teine, but still a small, signiﬁcant increase of homocysteine 
can be observed, ranging from 6% to 20%. Other ﬁbrates 
have not been tested in conjunction with vitamins. Recently, 
other effects of folic acid added to fenoﬁbrate have been 
reported: the combination of fenoﬁbrate and folic acid re-
duced oxidized LDL-cholesterol and von Willebrand factor 
and thrombomodulin, biochemical markers of endothelial 
function (Mayer et al 2005). However, these results have 
been obtained in a small study in 18 volunteers and await 
conﬁrmation in other studies. 
HMG-CoA reductase inhibitors (statins)
Statins are widely used for the prevention of cardiovascular 
disease through the reduction of total cholesterol and espe-
cially LDL-cholesterol. With respect to homocysteine, they 
have mainly been used as comparison to a ﬁbrate arm dur-
ing short-term studies (de Lorgeril et al 1999; Melenovsky 
et al 2002; Sebestjen et al 2004; Milionis et al 2003). No 
study directly compared different statins. In the prospective 
AFCAPS/TexCAPS trial, a small reduction of homocysteine 
during one year of treatment with lovastatin was observed 
(Ridker et al 2002), however, this ﬁnding was statistically 
signiﬁcant, but the biological meaning of homocysteine 
reduction of –0.4 µmol/L may be questioned. 
From these and other studies, it can be concluded that 
statins do not inﬂuence homocysteine concentrations sig-
niﬁcantly. Furthermore, the concurrent administration of 
statins and vitamins was investigated in a pilot study of the 
SEARCH trial (MacMahon et al 2000), revealing that there is 
obviously no effect of the statin component, as the reduction 
of plasma homocysteine levels was similar in the vitamin 
group and the vitamin plus statin group. 
Nicotinic acid (niacin) 
The cholesterol-lowering effect of high doses of nicotinic 
acid was recognized as early as 1955 (Altschul et al 1955). 
Nicotinic acid lowers total cholesterol, but is at present 
re-considered since it is also able to increase the protective 
HDL-cholesterol concentration (Parhofer 2005). While the 
physiological dose of the vitamin is about 20 mg per day, 
the lipid-lowering effect requires administration of 1.5–3 g 
of nicotinic acid (Knopp 1999). A ﬁrst analysis in humans 
whether niacin may also inﬂuence homocysteine was made 
in the Arterial Disease Multiple Intervention Trial (ADMIT). 
Homocysteine was measured in subgroups treated either 
with niacin (n = 24) or placebo (n = 22). After 18 and 48 
weeks of treatment with niacin, average homocysteine levels 
were 21.1 and 19.9 µmol/L in the niacin group and 11.5 and   
11.6 µmol/L in the placebo group, respectively. Unfortu-
nately, no vitamin levels during follow-up were presented 
(Garg et al 1999). In animal studies, high doses of niacin were 
associated with lower levels of vitamin B6 and increased 
homocysteine concentrations (Basu and Mann 1997). Ad-
dition of vitamin B6 corrected the hyperhomocysteinemia. 
Since nicotinic acid is excreted in the methylated form, ad-
ministration of this drug increases the total methyl demand 
substantially. Thus, formation of S-adenosylhomocysteine 
from S-adenosylmethionine is increased. Single cases of 
drastically increased homocysteine concentrations after 
niacin administration have been reportet (Wang et al 2001). 
There is no study in humans that considered vitamin B6 
during niacin therapy. On the other hand, a recent study 
which compared the effect of simvastatin or simvastatin plus 
niacin (2 × 1000 mg/d) did not observe a higher frequency of 
hyperhomocysteinemia in the simvastatin plus niacin group 
(any homocysteine > 15 µmol/L, measured bimonthly for 
38 months: 4% in the simvastatin group versus 9% in the 
combination group, p = 0.191). However, this report did not 
provide means or median values (Zhao et al 2004).
Thus, at present, the effect of niacin on homocysteine and 
related vitamins in humans is unclear, although there is some 
evidence that niacin may raise homocysteine. Further studies 
are needed to clarify this issue, especially when keeping in 
mind the rising prescription of niacin. 
n3-fatty acids
N3-fatty acids in relatively high doses (2–6 g/d) are used 
in the treatment of severe hypertriglyceridemia. One of the 
very early studies on homocysteine reported that admin-
istration of n3 fatty acids reduces plasma homocysteine 
(Olszewski and McCully 1993). Since then, a number of 
studies has been published on this association, however, 
with conﬂicting results. There are studies that report an 
increase of homocysteine after administration of ﬁsh oil 
or pure n3-fatty acids (Bourque et al 2003; Piolot et al 
2003), compared with studies that observed no effect on 
homocysteine (Grundt et al 1999), or even a decrease of 
homocysteine after administration of ﬁsh oil (Olszewski 
and McCully 1993; Grundt et al 2003; Zeman et al 2006). 
At a glance, the different results cannot be attributed to 
differences in study design, fatty acids used or exclusion 
criteria of study subjects. Thus, the effect of n3-fatty acids 
on homocysteine cannot be uniformly described at present. Vascular Health and Risk Management 2007:3(1) 104
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However, it has to be kept in mind that the effects of n3 
fatty acid on homocysteine described have been small, 
ranging from increase by 15%–20% or decrease in the same 
magnitude. Therefore, chance ﬁndings are also likely. In 
addition, some doubts to the data may be allowed since 
there is no obvious hypothesis on the mechanism by which 
n3-fatty acids would alter homocysteine levels. One link 
may be vitamin B6 which serves as coenzyme both in the 
homocysteine-transsulfuration pathway but also as cofactor 
of the d6 desaturase which is involved in PUFA metabolism. 
Recently, in a rat study an elevated homocysteine con-
centration was measured in vitamin B6-deﬁcient animals 
compared with animals with normal vitamin B6. Even more 
interestingly, signiﬁcantly higher homocysteine levels were 
observed in vitamin B6 deﬁcient animals receiving diet 
high in polyunsaturated fatty acids (PUFA), compared with 
vitamin B6 deﬁcient animals receiving a diet with saturated 
fatty acids (Cabrini et al 2005). It is not known at present, 
whether these results are also applicable in humans. Un-
fortunately, studies on PUFA supplementation in humans 
did not provide vitamin B6 levels at all. Obviously, in rats, 
homocysteine is closer related to vitamin B6 metabolism 
than in humans (Basu and Mann 1997). Further studies are 
necessary to clarify this issue. 
Conclusion–lipid lowering drugs
Homocysteine is increased by administration of ﬁbric acid 
derivatives. Statins do not inﬂuence homocysteine levels, 
while the effect of nicotinic acid and n3-fatty acids is less 
clear. Concurrent vitamin administration with ﬁbrates can 
attenuate the homocysteine increase substantially. 
Table 2 Effect of ﬁbrates on homocysteine concentration (mean ± standard deviation, unless otherwise noted) 
Study  N  treatment  tHcy before  tHcy after   % change   P 
    Fenoﬁbrate        
de Lorgeril 1999  29  200 mg/d,12 weeks  11.4 ± 3.5  16.6 ± 5.2  + 56 %  <0.001
Dierkes 1999  10  200 mg/d, 6 weeks  13.1  20.0  + 44 (–8 ± 85) %b  a<0.001
Landray 1999  8  according to renal  15.1  21.8  + 44 %  ap = 0.03
    failure, 8 weeks         
Giral 2001  29  200 mg/d, 6 months  12.3 ± 3.9  16.2 ± 4.6  + 32 %  <0.001
Bissonnette 2001  20  200 mg/d, 8 weeks  10.3 ± 3.3  14.1 ± 3.8  + 37 %  <0.001
Dierkes 2001  25  200 mg/d, 6 weeks  10.7  14.0  44 ±   a<0.001
          47 %b
Westphal 2001  22  200 mg/d, 6 weeks  10.7  14.4  + 35 %  a<0.001
Stulc 2001  11  200 mg/d, 9 weeks  12.3 ± 3.2  19.1 ± 7.2  + 55 %  <0.001
Melenovsky 2002  15  200 mg/d, 10 weeks  12.4 ± 2.7  16.9 ± 3.7  + 36 %  <0.001
Melenovsky 2003  19  200 mg/d, 65 ± 18 days  11.5 ± 3.0  17.5 ± 6.5  + 52 %  not provided
Mayer 2003  24  200 mg/d, 3 months  10.0 ± 2.9  14.2 ± 2.9  + 42 %  not provided
Milionis 2003  22  200 mg/d, 12 weeks  10.3 ± 3.3  14.2 ± 3.6  + 38 %  <0.001
Genest 2004  418  200 mg/d, 3 years  11.0 ± 5.6  16.5 ± 10.7  + 55 %  <0.001
DAIS-Study     
    Bezaﬁbrate        
Dierkes 1999  10  400 mg/d, 6 weeks  11.9  15.5  +17 (–14 –65) %b  ap = 0.02
Jonkers 1999  16  400 mg/d, 6 weeks  11.9 ± 2.1  14.1 ± 2.9  + 18 %  <0.001
Harats 2001  12  400 mg/d, 6 weeks  8.2 ± 2.3  6.8 ± 1.4  –17 %  p = 0.22
           
    Ciproﬁbrate        
Harats 2001  26  100 mg/d, 12 weeks  6.8 ± 1.8  10.6 ± 4.3  + 56 %  <0.0001
           
    Gemﬁbrozil        
Westphal 2001  22  900 mg/d, 6 weeks  12.9  12.4  –4 %  aNS
Syvänne 2004 
LOCAT-Study  395  900 mg/d, 16 months  12.6  14.1  + 11.9%   a<0.0001
Notes: aMedian; bcalculated from individual data.
Abbreviations:  ACE inhibitor, angiotensin-converting enzyme inhibitor; BIP, bezaﬁbrate Infarction Prevention; CAD, coronary artery disease; CI, conﬁdence interval; CVD, 
cardiovascular disease; DAIS, Diabetes Atherosclerosis Intervention Study; FIELD, Fenoﬁbrate Intervention and Event Lowering in Diabetes; GFR, glomerular ﬁltration 
rate; FA, folic acid; HCT, hydrochlorothiazide; LOCAT, Lopid Coronary Angiography Trial; MTHFR, methylenetetrahydrofolate reductase; PPARα, peroxisome-proliferation 
activated receptor alpha; PUFA, polyunsaturated fatty acids; RR, relative risk; homocysteine, total homocysteine.Vascular Health and Risk Management 2007:3(1) 105
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Table 3 Lipid-lowering and anti-hypertensive drugs that elevate homocysteine 
Drug  Effect on homocysteine   Suggested mechanisms  Evidence from 
Fibric acid derivatives  increase of homocysteine:   reduction of glomerular function  Human studies, cross-sectional 
  + 40% fenoﬁbrate  increased creatin/creatinine  and clinical trials mechanistic 
  +20% bezaﬁbrate  metabolism  studies in rodents
  + 20% gemﬁbrozil   PPARα-activation 
Niacin   increase of fasting  
  homocysteine, amount unclear   effect on vitamin B6 metabolism  Human studies,mechanistic  
    increased methylation demand  studies in rodents
Diuretics  increase of fasting homocysteine   decreased glomerular ﬁltration rate  Human studies, cross-sectional 
  +20% hydrochlorothiazide     and one clinical trial 
Anti-hypertensive drugs 
Drug treatment strategies to lower blood pressure vary widely 
throughout the world (Nygard et al 1997). Many studies have 
recently revealed that homocysteine is positively correlated 
with blood pressure, especially the systolic component (Ny-
gard et al 1995; Jaques et al 2001; Sutton-Tyrrell et al 1997); 
however, this association is not evident in other studies 
(van Guldener 2003). The effects of different antihyperten-
sive agents on plasma homocysteine levels have not been 
tested extensively. Recent studies have reported associations   
between diuretic drug therapy for the treatment of hyper-
tension with homocysteine elevations (Nygard et al 1995). 
Data from the Framingham Offspring Study showed a highly 
signiﬁcant positive association between the use of antihyper-
tensive medication and homocysteine concentrations (Jaques 
et al 2001). Such treatment-associated increases in homocys-
teine may be a cause for concern if they were to reduce the 
cardio-protective effects of lowering of blood pressure.
Diuretics
Recent studies have reported that use of diuretics as an 
antihypertensive drug is associated with increased levels 
of homocysteine. Morrow and colleagues (1999) analyzed 
plasma concentrations of homocysteine, vitamins B6 and 
B12, and RBC folate in 17 hypertensive patients receiving 
long-term diuretic therapy and 17 hypertensive patients not 
taking diuretics The mean serum homocysteine concentra-
tion of patients taking diuretics (17.9 ± 1.7 µmol/L) was 
signiﬁcantly higher than for patients not taking diuretics 
(10.3 ± 1.0 µmol/L). The mean RBC folate concentration 
for patients taking diuretics (281 ± 18 ng/mL) was 
signiﬁcantly lower than that for patients not taking diuretics 
(431 ± 29 ng/mL). Serum vitamin B6 and vitamin B12 
concentrations were not signiﬁcantly different between the 
two groups. It has been known for many years that diuretics 
can cause a depletion of water-soluble vitamins (Montenero 
1980), although vitamin deﬁciency is not a common side 
effect of long-term diuretic use. 
In a small trial of 27 patients assigned to treatment with 
either hydrochlorothiazide (HCT) or an ACE inhibitor, 
Westphal et al (2003) measured homocysteine, creatinine, 
folate, vitamins B6 and B12 before and after 4–6 weeks 
of treatment. HCT raised homocysteine concentrations by 
28%, creatinine by 12% and decreased folate levels non-
signiﬁcantly by 26%. The underlying mechanism for the 
increase in homocysteine was attributed to a concomitant 
deterioration of renal function. The magnitude of the increase 
in homocysteine after HCT may be clinically relevant if this 
increases cardiovascular risk (Boushey et al 1995) and may 
counteract the desired cardiovascular protection conferred by 
lowering blood pressure. The extent to which the changes in 
homocysteine may explain the discrepant results on risk of 
coronary heart disease associated with differences in blood 
pressure mediated by HCT use (Kezdi et al 1992) is unclear. 
Possible adverse effects of HCT have been chieﬂy attributed 
to increases in LDL-cholesterol and glucose or hypokalaemia 
(Freis 1995), but increases in homocysteine may now be 
added to this side effect proﬁle of HCT therapy. 
Beta blockers
Korkmaz et al (2003) showed in a preliminary study, that 
metoprolol therapy signiﬁcantly decreased homocysteine 
levels both in the ﬁrst and ﬁfth months of treatment. Two 
years later, Atar et al (2005) investigated in a prospective 
study the effects of beta-blocker therapy on homocysteine 
levels in patients with hypertension. 120 patients with newly 
diagnosed hypertension were enrolled. All patients received 
metoprolol succinate 100 mg/day initially. If blood pressure 
was above normal on the 15th day of follow-up, the meto-
prolol dosage was doubled. Homocysteine levels decreased 
signiﬁcantly by the end of the fourth month when compared 
with basal values (13.5+/–4.5 µmol/L vs 12.4+/–4.9 µmol/L; Vascular Health and Risk Management 2007:3(1) 106
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p = 0.001). There was no relation between homocysteine 
level and blood pressure control. There was a signiﬁcant 
decrease in homocysteine levels in the women treated in this 
study (p = 0.001); however, this effect was absent in men   
(p = 0.185). Sharabi et al (1999) studied hypertensive patients 
with coronary and cerebral atherothrombosis and discovered 
that homocysteine levels were lower in patients who were 
taking beta-blockers.
Other anti-hypertensive drugs  
and conclusion 
It is unclear whether other anti-hypertensive drugs, such as ACE 
inhibitors or calcium-channel blockers inﬂuence homocysteine 
concentrations since their effects have not been widely studied. 
In summary, most of the available evidence suggests that blood 
pressure lowering therapy with diuretics is associated with an 
increase of plasma homocysteine concentrations.
Implications and 
conclusions: Is drug-induced 
hyperhomocysteinemia important?
Recently, results of the ﬁrst randomized clinical trials on 
homocysteine lowering by vitamins in secondary preven-
tion have been become public (Schnyder et al 2001; Liem 
et al 2003; Lange et al 2004; Toole et al 2004). Results are, 
however, not encouraging that lowering homocysteine by   
vitamins will be effective in reducing cardiovascular morbidi-
ty or mortality in secondary prevention. However, even in the 
VISP study (Toole et al 2004), a high baseline homocysteine 
concentration was associated with worse outcome. Therefore, 
at present, the signiﬁcance of elevated homocysteine due to 
whatever cause is unclear. 
Current evidence shows that a clear, uniform homocyste-
ine increase can be expected in patients treated with ﬁbrates 
(fenoﬁbrate or bezaﬁbrate) and with thiazides (Table 2). 
For these drugs, the increase in homocysteine has been 
demonstrated in both observational studies and in clinical 
trials. In the case of ﬁbrates, it was shown that addition of vi-
tamins can reduce the drug induced hyperhomocysteinemia. 
There is now also a study that suggests beneﬁcial effects of 
the added folic acid on the endothelium and on anti-oxidative 
status (Mayer et al 2005). Whether the homocysteine increase 
is responsible for non-signiﬁcant results of prospective ran-
domized trials with fenoﬁbrate in secondary prevention can 
only be speculated at present. 
The evidence for a homocysteine increase associated with 
other lipid lowering drugs is less convincing. The discrepant 
results observed for niacin and n-3 fatty acids questions about 
whether these drugs really inﬂuence plasma homocysteine. 
There is a need for more data on niacin and homocysteine 
and ﬁsh oil and homocysteine, also with respect to vitamin 
B6, which might be an important confounder that has not 
been rewarded until now in humans. 
It has to be taken into account that the relative risk for 
cardiovascular events associated with an increase of homo-
cysteine are generally modest (Table 1). Therefore, it does not 
seem to be justiﬁed to discontinue treatment with thiazides 
or ﬁbrates because of the adverse effects on homocysteine 
concentrations. Physicians and their patients should be in-
formed about the possibility of combining these drugs with 
low doses of folic acid, vitamin B12 and B6 in order to enable 
them to an informed decision. 
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